Print

Aradigm Corporation (ARDM) Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin  
10/20/2010 9:57:21 AM

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced positive top line data from its recently concluded 6-month Phase 2b study (ORBIT-2) with Aradigm’s once-daily dual release ciprofloxacin for inhalation (DRCFI, ARD-3150) in patients with non-cystic fibrosis bronchiectasis.
//-->